Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
04/2003
04/08/2003US6545149 Synthesis and crystallization of piperazine ring-containing compounds
04/08/2003US6545108 Catalysts containing N-pyrrolyl substituted nitrogen donors
04/08/2003US6545071 Stabilizer mixtures
04/08/2003US6545055 Amidino-phenyl or -naphthyl aromatic amide derivatives
04/08/2003US6545054 Alkenyl and alkynyl compounds as inhibitors of factor Xa
04/08/2003US6545038 Heterocyclic metalloprotease inhibitors
04/08/2003US6545037 Thromboxane A2 (TXA2) receptor and 5HT2 serotonergic receptor antagonists; 3-(6-(((4-chlorophenyl)sulphonyl)amino)-3-((2-(4-methyl-1 -piperazinyl)phenoxy)methyl)-5,6, 7,8-tetrahydro-1-naphthyl)propanoic acid for example
04/08/2003US6545025 Antiinflammatroy agents; antiallergens
04/08/2003US6545024 Complexing acetone with sulfoxides such as Rabeprazole, Lansoprazole, Omeprazole or Pantoprazole; inhibitors of gastric acid secretion and anti-ulcer agents or as intermediates for production of medicines
04/08/2003US6545023 For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane
04/08/2003US6545022 Treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders
04/08/2003US6545020 Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties
04/08/2003US6545015 Useful in therapy of bacterial infections, fungal infections
04/08/2003US6545011 PARP (poly(adenosine 5'-diphospho-ribose) polymerase) inhibitors
04/08/2003US6545008 Pyrimidine derivatives and processes for the preparation thereof
04/08/2003US6545005 Mediators of hedgehog signaling pathways, compositions and uses related thereto
04/08/2003US6545004 Treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
04/08/2003US6544992 Carbonylamino pyrrolidine and piperidine derivatives
04/08/2003US6544990 Such as N-(4-chlorobenzyl)-8-(4-hydroxybut-1-ynyl)-1-methyl-6-(morpholin-4-ylmethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide for treatment against herpes viruse; enzyme inhibitors
04/08/2003US6544987 Compounds, compositions, and methods for stimulating neuronal growth and elongation
04/08/2003US6544985 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits
04/08/2003US6544984 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
04/08/2003US6544981 Anticoagulants, cardiovascular disorders
04/08/2003US6544976 Treating disorders characterized by neuronal damage caused by disease or trauma, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, diabetic neuropathy and Bell's palsy.
04/08/2003US6544970 Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative
04/08/2003CA2224983C Triazole antifungal agents
04/08/2003CA2123548C Piperazine derivatives
04/08/2003CA2112165C Bicyclic amine derivatives
04/08/2003CA2097824C Functionalized vinyl azoles and their use
04/08/2003CA2053216C Saturated hydroxyalkylquinoline acids as leukotriene antagonists
04/07/2003WO2002032866A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
04/03/2003WO2003027275A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
04/03/2003WO2003027185A1 Novel anthrapyridone compounds, water-base magenta ink compositions, and ink-jet recording process
04/03/2003WO2003027107A1 Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
04/03/2003WO2003027105A1 Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
04/03/2003WO2003027102A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003027101A1 Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
04/03/2003WO2003027100A1 Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
04/03/2003WO2003027099A1 Arthropodicidal anthranilamides
04/03/2003WO2003027098A1 Benzimidazole compound, process for producing the same, and use thereof
04/03/2003WO2003027097A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
04/03/2003WO2003027096A1 Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
04/03/2003WO2003027095A1 Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors
04/03/2003WO2003027094A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003WO2003027085A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003WO2003027080A1 3-substituted-4-pyrimidone derivatives
04/03/2003WO2003027078A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
04/03/2003WO2003027076A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027074A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders
04/03/2003WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003WO2003027068A2 Substituted amines for the treatment of neurological disorders
04/03/2003WO2003026666A1 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
04/03/2003WO2003026665A1 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
04/03/2003WO2003026664A1 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026662A1 Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
04/03/2003WO2003026652A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
04/03/2003WO2003026649A1 Methods of increasing endogenous testosterone levels
04/03/2003WO2003026648A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
04/03/2003WO2003026647A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
04/03/2003WO2003026587A2 Compounds useful for treating hepatitus c virus
04/03/2003WO2003026415A2 Insecticidal diamides
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002092563A3 Protease inhibitors
04/03/2003WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
04/03/2003WO2002085312A3 Process for purifying 6-methoxy omeprazole
04/03/2003WO2002039954A3 Novel compounds
04/03/2003WO2000038618A3 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
04/03/2003US20030065187 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
04/03/2003US20030065184 Stabilizer for addition polymer
04/03/2003US20030065179 Diabetic therapy
04/03/2003US20030065176 Anticoagulant; cardiovascular disorders
04/03/2003US20030065034 Antiinflammatory agents; coupling sulfonyl halide with aromatic amine compound
04/03/2003US20030065009 Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
04/03/2003US20030065007 Analgesics; psychological disorders; antidepressants
04/03/2003US20030065004 Androgen receptor modulators and methods for use thereof
04/03/2003US20030064997 Novel compounds
04/03/2003US20030064995 Antidepressants, anxiolytic agents
04/03/2003US20030064992 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
04/03/2003US20030064991 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
04/03/2003US20030064982 Pyrazole compounds useful as protein kinase inhibitors
04/03/2003US20030064981 Anticancer agents; antidiabetic agents; Alzheimer's disease
04/03/2003US20030064980 Respiratory system disorders; antiinflammatory agents
04/03/2003US20030064954 Gene therapy; vaccines; calcium channel blockers; cardiovascular disorders
04/03/2003US20030064332 Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
04/03/2003CA2726702A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
04/03/2003CA2688860A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/03/2003CA2461603A1 Substituted amines for the treatment of neurological disorders
04/03/2003CA2461467A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
04/03/2003CA2461363A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003CA2461360A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003CA2461128A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders
04/03/2003CA2461095A1 Process for making substituted pyrazoles
04/03/2003CA2461080A1 Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
04/03/2003CA2460000A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
04/03/2003CA2458661A1 Methods of increasing endogenous testosterone levels
04/02/2003WO2002030891A1 Aliphatic nitrogenous five-membered ring compounds
1 ... 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 ... 1080